| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
158.12(B) |
| Last
Volume: |
2,436,955 |
Avg
Vol: |
2,722,982 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
12,096 |
21,654 |
43,486 |
| Total Sell Value |
$0 |
$3,300,412 |
$5,808,718 |
$11,189,871 |
| Total People Sold |
0 |
2 |
3 |
6 |
| Total Sell Transactions |
0 |
2 |
3 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kullman Ellen Jamison |
Director |
• • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
7,931 |
|
- |
|
| Garland Greg C. |
Director |
• • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
9,861 |
|
- |
|
| Williams R Sanders |
Director |
• • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
5,246 |
|
- |
|
| Austin Wanda M |
Director |
• • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
4,031 |
|
- |
|
| Jacks Tyler |
Director |
• • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
12,410 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
837 |
5,093 |
|
- |
|
| Sugar Ronald D |
Director |
• • – |
2021-05-12 |
4 |
AS |
$250.59 |
$250,590 |
D/D |
(1,000) |
15,927 |
|
-14% |
|
| Sugar Ronald D |
Director |
• • – |
2021-05-12 |
4 |
OE |
$71.64 |
$71,640 |
D/D |
1,000 |
16,927 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2021-05-11 |
4 |
S |
$252.51 |
$631,272 |
D/D |
(2,500) |
12,461 |
|
15% |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2021-05-11 |
4 |
OE |
$162.60 |
$406,500 |
D/D |
2,500 |
14,961 |
|
- |
|
| Williams R Sanders |
Director |
• • – |
2021-05-07 |
4 |
AS |
$251.78 |
$62,945 |
D/D |
(250) |
4,409 |
|
-15% |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$4,074 |
D/D |
(17) |
8,266 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$13,180 |
D/D |
(55) |
12,461 |
|
- |
|
| Johnston Lori A |
EVP, HR |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$80,279 |
D/D |
(335) |
37,365 |
|
- |
|
| Gordon Murdo |
EVP Global Commercial Ops |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$187,398 |
D/D |
(782) |
44,848 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$131,323 |
D/D |
(548) |
46,633 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$52,721 |
D/D |
(220) |
44,787 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$178,532 |
D/D |
(745) |
44,472 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$164,153 |
D/D |
(685) |
51,108 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2021-05-03 |
4 |
D |
$239.64 |
$682,974 |
D/D |
(2,850) |
594,173 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2021-05-01 |
4 |
D |
$239.64 |
$4,314 |
D/D |
(18) |
8,283 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2021-05-01 |
4 |
D |
$239.64 |
$14,858 |
D/D |
(62) |
12,516 |
|
- |
|
| Johnston Lori A |
EVP, HR |
• • – |
2021-05-01 |
4 |
D |
$239.64 |
$85,072 |
D/D |
(355) |
37,700 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2021-05-01 |
4 |
D |
$239.64 |
$139,231 |
D/D |
(581) |
47,181 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2021-05-01 |
4 |
D |
$239.64 |
$33,310 |
D/D |
(139) |
45,007 |
|
- |
|
2150 Records found
|
|
Page 10 of 86 |
|
|
0.60 (0.22%) 
